SLNO Soleno Therapeutics Inc

Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Piper Jaffray 29th Annual Healthcare Conference, taking place November 28-29 in New York City.

Presentation Details:Date: Wednesday, November 29Time:  12:00pm Eastern TimeLocation:  Lotte New York Palace Hotel, Track 4, Holmes 2 Ballroom

About Soleno Therapeutics, Inc.Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.  The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program in early 2018.  Soleno, through its wholly-owned subsidiary, Capnia, Inc., continues to market Capnia’s innovative medical device, the CoSense® End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. It is expected that CoSense will be monetized and will not be a focus for the company in the long-term.

For more information, please visit www.soleno.life. 

CONTACT:Brian RitchieLifeSci Advisors, LLC212-915-2578